Feedback
Settings

Settings

Goto Application

6,055 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(USVMJSALORZVDV-SDBHATRESA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 606
1.12409237Methods and models for assessing efficacy of immunotherapies
US - 09.09.2025
Int.Class A01K 67/0278
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
027New or modified breeds of vertebrates
0275Genetically modified vertebrates, e.g. transgenic
0278Knock-in vertebrates, e.g. humanised vertebrates
 Appl.No 18758838 Applicant The Jackson Laboratory Inventor Leonard D. Shultz

A method of identifying anti-tumor activity of a test substance is provided along with a genetically-modified, immunodeficient mouse and methods of use, wherein the genetically-modified, immunodeficient mouse enables in vivo investigation of the interactions between the human immune system and human cancer.

2.WO/2025/184665SENESCENCE VACCINE
WO - 04.09.2025
Int.Class A61K 35/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
 Appl.No PCT/US2025/018210 Applicant IMMORTA BIO, INC. Inventor ICHIM, Thomas E.
Methods, and compositions of matter useful for enhancing activity of endogenous and/or exogenous regenerative cells by selectively eliminating senescent cells through induction of immunity against said senescent cells or components thereof. Fusion of autologous patient cells made senescent, autologous antigen presenting cells and utilized as a vaccine. Autologous fibroblasts can be made senescent by genotoxic stress and fused with dendritic cells. Said dendritic cells may be generated from circulating monocytes, CD34 cells or autologous iPSC cells.
3.WO/2025/181803COMBINED TREATMENT WITH A SIRPalpha-4-1BBL FUSION PROTEIN FOR CANCER
WO - 04.09.2025
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/IL2025/050192 Applicant KAHR MEDICAL LTD. Inventor PEREG, Yaron
Combined treatment with a SIRPα-4-lBBL fusion protein for cancer is provided. Accordingly, there is provided a combination of a SIRPa-4-lBBL fusion protein and at least two agents selected from the group consisting of an agent which inhibits activity or expression of a receptor-ligand combination PD1-PD-L1, an agent which inhibits activity or expression of a receptor-ligand combination VEGFR-VEGF, and Trifluridine/Tipiracil, for use in treating cancer in a subject in need thereof. Also provided a combination of a SIRPa-4-lBBL fusion protein and agent which inhibits a receptor tyrosine kinase signaling pathway, for use in treating cancer in a subject in need thereof.
4.WO/2025/180699UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE
WO - 04.09.2025
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
 Appl.No PCT/EP2025/000013 Applicant 3B PHARMACEUTICALS GMBH Inventor HÖHNE, Aileen
The present invention is related to a compound comprising a cyclic peptide of formula (I)
5.20250268839PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS
US - 28.08.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 18927572 Applicant Icahn School of Medicine at Mount Sinai Inventor Willem Mulder

The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.

6.20250268879METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE
US - 28.08.2025
Int.Class A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
 Appl.No 19088680 Applicant Poxel SA Inventor Sheila DeWitt

The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.

7.WO/2025/174713ASYMMETRIC LIPOSOMES FOR DRUG DELIVERY AND OTHER APPLICATIONS
WO - 21.08.2025
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2025/015327 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor WEITZ, David, A.
Some aspects of the present disclosure are generally related to systems including asymmetric liposomes, for example, for drug delivery. In some embodiments, the asymmetric liposomes facilitate the encapsulation of therapeutic agents. In some embodiments, the system may include a plurality of asymmetric liposome and a plurality of cells, e.g., within a subject. According to some embodiments, cells may uptake the asymmetric liposomes at an enhanced rate when compared to conventionally used symmetric liposomes, e.g., while also comparatively being less cytotoxic. In some embodiments, the enhanced rate of uptake of the asymmetric liposomes by cells improve delivery of a therapeutic agent encapsulated within the asymmetric liposomes to the cells. Still other aspects are generally directed to methods of making and using the liposomes, kits containing the liposomes, or the like.
8.20250257131Bispecific T Cell Engagers Targeting Tumor Antigens
US - 14.08.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18855100 Applicant The Wistar Institute of Anatomy and Biology Inventor David Weiner

The present invention provides bispecific binding molecules targeting CD3 and tumor antigens having increased expression and stability, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

9.WO/2025/171225COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS
WO - 14.08.2025
Int.Class C07D 249/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
249Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
 Appl.No PCT/US2025/014956 Applicant KOJIN THERAPEUTICS, INC. Inventor FURST, Laura
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of, e.g., inducers of, ferroptosis.
10.WO/2025/171226COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS
WO - 14.08.2025
Int.Class C07C 313/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
313Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
08Sulfenic acids; Derivatives thereof
18Sulfenamides
20having sulfur atoms of sulfenamide groups bound to acyclic carbon atoms
 Appl.No PCT/US2025/014958 Applicant KOJIN THERAPEUTICS, INC. Inventor FURST, Laura
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of, e.g., inducers of, ferroptosis.
# -